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Background
Hypertensive cardiac remodelling is a major risk factor for
cardiovascular morbidity and a leading cause of chronic
heart failure. The activation of the renin-angiotensin
system plays an important pathophysiological role in
hypertensive cardiac remodelling [1].
C-type natriuretic peptide (CNP) belongs to the
natriuretic peptide family. In the cardiovascular system,
CNP is secreted from endothelial cells and possibly
from cardiac fibroblasts, to act as autocrine/paracrine
hormone [2]. It activates the guanylyl cyclase B (GC-B)
receptor which synthesizes the second messenger
cGMP. In vitro the CNP/GC-B pathway inhibits the pro-
liferation and collagen synthesis of cardiac fibroblasts
[3]. Therefore, we aimed to study the cardiac effects of
synthetic CNP on Angiotensin II (Ang II)-induced car-
diac fibrosis and hypertrophy in vivo.
Methods and results
In primary cultured murine cardiomyocytes and cardiac
fibroblasts, CNP induced strong and concentration-
dependent increases in intracellular cGMP contents. In
comparison, the cGMP responses to ANP were much
smaller. To analyze CNP effects on Ang II-induced
arterial hypertension and cardiac remodelling, 2-months
old male C57/Bl6 mice were treated with vehicle
(saline), CNP, Ang II or Ang II combined with CNP
(12 mice per group). Osmotic minipumps filled with
Ang II (delivery of 2000 ng/Kg BW/min) and/or CNP
(50 ng/Kg/min) or vehicle were implanted subcuta-
neously during 2 weeks.
Infusion of Ang II provoked significant increases in
diastolic (by 12 ± 2 mmHg) and systolic blood pressure
levels (by 38 ± 3 mmHg; tail cuff measurements in
awake mice). These hypertensive effects were accompa-
nied by significant left ventricular (LV) hypertrophy
(with enhanced LV weight/BW and enlarged myocyte
diameters), LV interstitial fibrosis (quantified in sirius
red stained LV sections) and enhanced mRNA expres-
sion of the hypertrophy marker brain natriuretic peptide
(BNP, determined by qRT-PCR). Notably, CNP did not
alter baseline blood pressure levels or the hypertensive
reactions to Ang II. However, the peptide markedly and
significantly prevented the cardiac hypertrophic and
profibrotic actions of Ang II, as demonstrated at the
organ, cellular and molecular (BNP) level.
To evaluate cardiac contractile functions, LV pressure-
volume relationships were recorded by LV catheteriza-
tion in anesthetized mice. LV contractile and relaxation
functions of Ang II-treated mice were only mildly
altered, as evidenced by subtle changes in LV diastolic
pressures, contraction/relaxation rates, ejection fractions
and stroke work. LV end-systolic pressures were
enhanced, consistent with the enhanced afterload.
Remarkably, CNP did not alter baseline LV hemody-
namics but significantly improved LV contractility of
Ang II-treated mice. Lastly, LV mRNA expression levels
of the fibrosis markers collagen I and connective tissue
growth factor (CTGF) were analyzed by quantitative real
time RT-PCR. Ang II provoked ~2.5-fold increases in
collagen I and CTGF. Simultaneous infusion of CNP
significantly prevented the increases in collagen levels
and had no effect on CTGF.
Conclusion
In our experimental study infusion of a low dose CNP
largely prevented the deleterious structural cardiac
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changes which follow neurohormonal activation by
Ang II. These anti-remodelling effects of CNP possibly
account for the improved cardiac contractile functions.
Strikingly, these cardiac protective effects of CNP were
fully blood pressure independent. The view that aug-
mentation of cyclic GMP signaling in general benefits
heart failure patients is supported by the recent clinical
observation that a drug combining blockade of the Ang
II/AT1-receptor with inhibition of neprilysin, a peptidase
which degrades ANP and BNP, diminished the risks of
hospitalization and death [3]. The here presented and
other published experimental observations [4] suggest
that the CNP–cGMP pathway may also represent a tar-
get for heart-protecting therapies.
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